[Recent progress in clinical trials with antimetastatic drugs].
Progress in the genetic and molecular elucidation of the pathogenesis of cancer metastases has led to the identification of important molecules such as growth factors, signal transducing molecules, angiogenic factors, adhesion molecules and matrix metalloproteinases, which can be now target molecules for antimetastatic therapy. Many drugs designed and developed to therapeutically control such metastasis-related molecules are now in the clinical study stage. This paper reviews the recent progress of ongoing clinical trials in the U.S.A. and Europe.
Sone
S
S
Third Dept. of Internal Medicine, University of Tokushima School of Medicine, Japan.
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D005060:Europe; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D011480:Protease Inhibitors / Q000494:pharmacology; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; C112567:etaracizumab